SENJU PHARMACEUTICAL AND NOVALIQ ENTER INTO LICENSE AGREEMENT FOR NOV03 (PERFLUOROHEXYLOCTANE OPHTHALMIC SOLUTION) FOR THE TREATMENT OF DRY EYE DISEASE IN JAPAN
Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free technology, are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.